HRP20192140T1 - Režimi doziranja anti-folr1 imunokonjugata - Google Patents
Režimi doziranja anti-folr1 imunokonjugata Download PDFInfo
- Publication number
- HRP20192140T1 HRP20192140T1 HRP20192140TT HRP20192140T HRP20192140T1 HR P20192140 T1 HRP20192140 T1 HR P20192140T1 HR P20192140T T HRP20192140T T HR P20192140TT HR P20192140 T HRP20192140 T HR P20192140T HR P20192140 T1 HRP20192140 T1 HR P20192140T1
- Authority
- HR
- Croatia
- Prior art keywords
- immunoconjugate
- amino acid
- acid sequence
- antibody
- seq
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 102100035139 Folate receptor alpha Human genes 0.000 claims 8
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims 8
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 6
- 239000013612 plasmid Substances 0.000 claims 6
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 3
- 201000002628 peritoneum cancer Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- SVVGCFZPFZGWRG-OTKBOCOUSA-N maytansinoid dm4 Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)C(C)(C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 SVVGCFZPFZGWRG-OTKBOCOUSA-N 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Botany (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Imunokonjugat koji se veže na FOLR1 polipeptid za uporabu u liječenju raka koji eksprimira FOLR1, pri čemu imunokonjugat sadrži majtansinoid i njegovo antitijelo ili fragment koji veže antigen koji sadrži regiju određivanja komplementarnosti lakog lanca (VL) (CDR) - 1 od SEQ ID NO: 6, VL CDR-2 od SEQ ID NO: 7, VL CDR-3 od SEQ ID NO: 8, CDR-1 varijabilnog teškog lanca (VH) CDR-1 od SEQ ID NO: 9, VH CDR-2 od SEQ ID NO: 11 i VH CDR-3 od SEQ ID NO: 12, pri čemu je rak rak jajnika, rak peritoneuma, rak endometrija ili rak maternice, poželjno, gdje je rak rak jajnika koji eksprimira FOLR1 i pri čemu se imunokonjugat daje u dozi od 6 miligrama (mg) po kilogramu (kg) prilagođene idealne tjelesne težine (AIBW).
2. Imunokonjugat sukladno zahtjevu 1, naznačen time što antitijelo ili njegov antigen-vezujući fragment sadrži varijabilnu domenu teškog lanca koja sadrži SEQ ID NO: 3 i varijabilnu domenu lakog lanca koja sadrži SEQ ID NO: 4 ili SEQ ID NO: 5.
3. Imunokonjugat sukladno zahtjevu 1 ili 2, naznačen time, da imunokonjugat sadrži 1-10 majtansinoidnih molekula, poželjnije 2-5 majtansinoidnih molekula, a najpoželjnije 3-4 majtansinoidne molekule.
4. Imunokonjugat sukladno bilo kojem od zahtjeva 1-3, naznačen time da je majtansinoid DM4.
5. Imunokonjugat sukladno bilo kojem od zahtjeva 1-4, naznačen time da imunokonjugat sadrži veznik sulfo-SPDB.
6. Imunokonjugat sukladno bilo kojem od zahtjeva 1-3, naznačen time što antitijelo sadrži (i) teški lanac koji sadrži isti niz aminokiselina kao i aminokiselinski slijed teškog lanca kodiran plazmidom deponiranim u Američku tipsku kolekciju kultura (ATCC) kao PTA-10772 i (ii) laki lanac koji sadrži istu sekvencu aminokiselina kao sekvencu aminokiselina lakog lanca kodiranog plazmidom deponiranim u ATCC kao PTA-10774, pri čemu je majtansinoid DM4 i gdje je DM4 vezan na antitijelo sulfo-SPDB.
7. Imunokonjugat sukladno bilo kojem od zahtjeva 1-3, naznačen time što antitijelo sadrži (i) teški lanac koji sadrži aminokiselinsku sekvencu SEQ ID NO: 13 i (ii) laki lanac koji sadrži aminokiselinski slijed SEQ ID NO: 15, gdje je majtansinoid DM4, i gdje je DM4 povezan s antitijelom sulfo-SPDB.
8. Imunokonjugat sukladno bilo kojem od zahtjeva 1-7, naznačen time da je imunokonjugat formuliran za IV primjenu ili parenteralnu primjenu.
9. Imunokonjugat sukladno bilo kojem od zahtjeva 1-8, naznačen time što je rak rak jajnika ili rak peritoneuma, opcionalno je rak jajnika epitelijski rak jajnika ili gdje je rak jajnika rezistentan na platinu, recidiviran ili refraktorni.
10. Imunokonjugat koji se veže na FOLR1 polipeptid za uporabu u liječenju raka jajnika koji eksprimira FOLR1, pri čemu imunokonjugat sadrži DM4 i antitijelo koje sadrži (i) teški lanac koji sadrži isti niz aminokiselina kao i aminokiselinski slijed teškog lanca kodiran plazmidom deponiranim u Američku tipsku kolekciju kultura (ATCC) kao PTA-10772 i (ii) lakim lancem koji sadrži isti niz aminokiselina kao i aminokiselinski slijed lakog lanca kodiran plazmidom deponiranim u ATCC kao PTA -10774, pri čemu je DM4 povezan s antitijelom sulfo-SPDB, pri čemu je imunokonjugat formuliran za IV davanje i gdje se imunokonjugat daje u dozi od 6 miligrama (mg) po kilogramu (kg) prilagođene idealne tjelesne težine (AIBW).
11. Imunokonjugat koji se veže na FOLR1 polipeptid za uporabu u liječenju raka peritoneuma koji eksprimira FOLR1, pri čemu imunokonjugat sadrži DM4 i antitijelo koje sadrži (i) teški lanac koji sadrži isti slijed aminokiselina kao i aminokiselinski slijed teški lanac kodiran plazmidom deponiranom u Američkoj kolekciji tipičnih kultura (ATCC) kao PTA-10772 i (ii) laki lanac koji sadrži isti slijed aminokiselina kao i aminokiselinski slijed lakog lanca kodiran plazmidom deponiranom u ATCC kao PTA-10774, pri čemu je DM4 povezan s antitijelom sulfo-SPDB, pri čemu je imunokonjugat formuliran za IV davanje i gdje se imunokonjugat daje u dozi od 6 miligrama (mg) po kilogramu (kg) prilagođene idealne tjelesne težine (AIBW).
12. Imunokonjugat sukladno bilo kojem od zahtjeva 1-11, naznačen time da uzorak dobiven od pacijenta pokazuje FOLR1 ekspresiju mjereno imunohistokemijom (IHC).
13. Imunokonjugat sukladno zahtjevu 12, naznačen time da uzorak ima intenzitet bojanja od najmanje 2 hetero, najmanje 2 homo, najmanje 3 hetero ili najmanje 3 homo.
14. Imunokonjugat prema bilo kojem od zahtjeva 1-13, naznačen time što se imunokonjugat daje jednom u tri tjedna ili jednom u četiri tjedna.
15. Imunokonjugat prema zahtjevu 10 ili 11, naznačen time, da imunokonjugat sadrži 1-10 majtansinoidnih molekula po antitijelu, poželjnije 2-5 majtansinoidnih molekula po antitijelu, i najpoželjnije 3-4 majtansinoidne molekule po antitijelu.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361888337P | 2013-10-08 | 2013-10-08 | |
US201361888365P | 2013-10-08 | 2013-10-08 | |
US201461948363P | 2014-03-05 | 2014-03-05 | |
US201462004815P | 2014-05-29 | 2014-05-29 | |
PCT/US2014/059716 WO2015054400A2 (en) | 2013-10-08 | 2014-10-08 | Anti-folr1 immunoconjugate dosing regimens |
EP14852834.2A EP3055332B1 (en) | 2013-10-08 | 2014-10-08 | Anti-folr1 immunoconjugate dosing regimens |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20192140T1 true HRP20192140T1 (hr) | 2020-03-06 |
Family
ID=52813740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20192140TT HRP20192140T1 (hr) | 2013-10-08 | 2019-11-28 | Režimi doziranja anti-folr1 imunokonjugata |
Country Status (28)
Country | Link |
---|---|
US (2) | US20150132323A1 (hr) |
EP (2) | EP3055332B1 (hr) |
JP (5) | JP6463744B2 (hr) |
KR (7) | KR20240027861A (hr) |
CN (1) | CN106164093A (hr) |
AU (4) | AU2014331964C1 (hr) |
BR (1) | BR112016007479A2 (hr) |
CA (1) | CA2926325C (hr) |
CY (1) | CY1122449T1 (hr) |
DK (1) | DK3055332T3 (hr) |
ES (1) | ES2759426T3 (hr) |
HK (1) | HK1226671A1 (hr) |
HR (1) | HRP20192140T1 (hr) |
HU (1) | HUE046696T2 (hr) |
IL (3) | IL298044A (hr) |
LT (1) | LT3055332T (hr) |
MX (2) | MX2016004411A (hr) |
MY (1) | MY174670A (hr) |
NZ (2) | NZ757964A (hr) |
PL (1) | PL3055332T3 (hr) |
PT (1) | PT3055332T (hr) |
RS (1) | RS59644B1 (hr) |
RU (1) | RU2696579C2 (hr) |
SG (3) | SG10201907042PA (hr) |
SI (1) | SI3055332T1 (hr) |
UA (1) | UA119541C2 (hr) |
WO (1) | WO2015054400A2 (hr) |
ZA (1) | ZA201902009B (hr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
SG193514A1 (en) * | 2011-04-01 | 2013-10-30 | Immunogen Inc | Methods for increasing efficacy of folr1 cancer therapy |
KR102617499B1 (ko) | 2012-08-31 | 2023-12-22 | 이뮤노젠 아이엔씨 | 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트 |
WO2014186403A2 (en) * | 2013-05-14 | 2014-11-20 | Immunogen Inc. | Anti-folr1 immunoconjugate dosing regimens |
CN105814079B (zh) | 2013-08-30 | 2021-02-09 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
CN108601828B (zh) * | 2015-09-17 | 2023-04-28 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
RU2019141270A (ru) * | 2017-05-16 | 2021-06-16 | Иммуноджен, Инк. | Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител |
US10596270B2 (en) * | 2017-09-18 | 2020-03-24 | Sutro Biopharma, Inc. | Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates |
CA3091683A1 (en) | 2018-03-13 | 2019-09-19 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
WO2020016661A2 (en) * | 2018-07-09 | 2020-01-23 | Multitude Inc. | Antibodies specific to folate receptor alpha |
WO2020223221A1 (en) | 2019-04-29 | 2020-11-05 | Immunogen, Inc. | Biparatopic fr-alpha antibodies and immunoconjugates |
WO2022256507A1 (en) * | 2021-06-04 | 2022-12-08 | Immunogen, Inc. | Treatment of cancer in patients with soluble fr-alpha |
WO2023102077A1 (en) * | 2021-12-01 | 2023-06-08 | Sutro Biopharma, Inc. | Anti-folate receptor conjugate cancer therapy |
CN116333135A (zh) * | 2021-12-24 | 2023-06-27 | 百奥泰生物制药股份有限公司 | 抗FRα抗体及其抗体药物偶联物和用途 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4563304A (en) | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
US6706484B1 (en) | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
EP1011694A4 (en) * | 1996-11-15 | 2000-11-15 | Baxter Int | TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION |
ES2353268T3 (es) | 1999-07-02 | 2011-02-28 | Morphosys Ag | Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est. |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
GB0202319D0 (en) | 2002-02-01 | 2002-03-20 | Calex Electronics Ltd | Apparatus |
WO2004082463A2 (en) * | 2003-03-17 | 2004-09-30 | Medical College Of Ohio | Folate receptor gene modulation for cancer diagnosis and therapy |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
US20080312425A1 (en) | 2004-08-30 | 2008-12-18 | Lonza Biologics Plc. | Ion Exchange Chromatography and Purification of Antibodies |
RU2007139912A (ru) * | 2005-03-30 | 2009-05-10 | Пердью Рисерч Фаундейшн (Us) | Способ прогнозирования течения рака на основе количественного анализа клеточного рецептора витамина фолата |
US20090162374A1 (en) * | 2005-09-14 | 2009-06-25 | Geraghty Daniel E | Specific removal of activated immune cells |
EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
EP2242762B1 (en) | 2008-01-18 | 2015-12-16 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
WO2009094456A2 (en) * | 2008-01-22 | 2009-07-30 | Johns Hopkins University | Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection |
EP2276506A4 (en) | 2008-04-30 | 2014-05-07 | Immunogen Inc | EFFICIENT CONJUGATES AND HYDROPHILIC BINDER |
KR20230003298A (ko) | 2008-04-30 | 2023-01-05 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
MX2011001555A (es) * | 2008-12-19 | 2011-04-14 | Graceway Pharmaceuticals Llc | Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica. |
BR112012009250A2 (pt) * | 2009-10-21 | 2017-06-20 | Immunogen Inc | composição compreendendo conjugado anti-cd56-maitansinoide e uso da mesma |
SG10201501342UA (en) * | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
US8530122B2 (en) | 2010-07-30 | 2013-09-10 | Konica Minolta Business Technologies, Inc. | Foil transferring face forming toner and image forming method |
AU2011323124C1 (en) * | 2010-11-05 | 2016-09-22 | Eisai Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
SG193514A1 (en) * | 2011-04-01 | 2013-10-30 | Immunogen Inc | Methods for increasing efficacy of folr1 cancer therapy |
WO2012138749A1 (en) | 2011-04-04 | 2012-10-11 | Immunogen, Inc. | Methods for decreasing ocular toxicity of antibody drug conjugates |
KR102617499B1 (ko) * | 2012-08-31 | 2023-12-22 | 이뮤노젠 아이엔씨 | 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트 |
NZ713868A (en) * | 2013-04-08 | 2021-12-24 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
WO2014186403A2 (en) * | 2013-05-14 | 2014-11-20 | Immunogen Inc. | Anti-folr1 immunoconjugate dosing regimens |
CN105814079B (zh) * | 2013-08-30 | 2021-02-09 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
CN108601828B (zh) * | 2015-09-17 | 2023-04-28 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
-
2014
- 2014-10-08 US US14/509,809 patent/US20150132323A1/en active Pending
- 2014-10-08 RU RU2016114708A patent/RU2696579C2/ru active
- 2014-10-08 EP EP14852834.2A patent/EP3055332B1/en active Active
- 2014-10-08 WO PCT/US2014/059716 patent/WO2015054400A2/en active Application Filing
- 2014-10-08 NZ NZ757964A patent/NZ757964A/en unknown
- 2014-10-08 PL PL14852834T patent/PL3055332T3/pl unknown
- 2014-10-08 KR KR1020247005572A patent/KR20240027861A/ko active Application Filing
- 2014-10-08 MX MX2016004411A patent/MX2016004411A/es unknown
- 2014-10-08 DK DK14852834T patent/DK3055332T3/da active
- 2014-10-08 KR KR1020217029508A patent/KR20210118220A/ko not_active Application Discontinuation
- 2014-10-08 SG SG10201907042PA patent/SG10201907042PA/en unknown
- 2014-10-08 SG SG11201602361UA patent/SG11201602361UA/en unknown
- 2014-10-08 SG SG10202102555TA patent/SG10202102555TA/en unknown
- 2014-10-08 UA UAA201604168A patent/UA119541C2/uk unknown
- 2014-10-08 CA CA2926325A patent/CA2926325C/en active Active
- 2014-10-08 LT LTEP14852834.2T patent/LT3055332T/lt unknown
- 2014-10-08 JP JP2016521270A patent/JP6463744B2/ja active Active
- 2014-10-08 MY MYPI2016000551A patent/MY174670A/en unknown
- 2014-10-08 KR KR1020207014364A patent/KR20200058592A/ko active Application Filing
- 2014-10-08 IL IL298044A patent/IL298044A/en unknown
- 2014-10-08 EP EP19199163.7A patent/EP3653228B1/en active Active
- 2014-10-08 CN CN201480055444.3A patent/CN106164093A/zh active Pending
- 2014-10-08 KR KR1020227033036A patent/KR20220136468A/ko not_active Application Discontinuation
- 2014-10-08 RS RS20191523A patent/RS59644B1/sr unknown
- 2014-10-08 AU AU2014331964A patent/AU2014331964C1/en active Active
- 2014-10-08 BR BR112016007479A patent/BR112016007479A2/pt not_active Application Discontinuation
- 2014-10-08 ES ES14852834T patent/ES2759426T3/es active Active
- 2014-10-08 HU HUE14852834A patent/HUE046696T2/hu unknown
- 2014-10-08 SI SI201431419T patent/SI3055332T1/sl unknown
- 2014-10-08 KR KR1020167012025A patent/KR102115217B1/ko active IP Right Review Request
- 2014-10-08 PT PT148528342T patent/PT3055332T/pt unknown
- 2014-10-08 KR KR1020217010200A patent/KR102303874B1/ko active IP Right Grant
- 2014-10-08 NZ NZ718766A patent/NZ718766A/en unknown
- 2014-10-08 KR KR1020237034405A patent/KR102639861B1/ko active IP Right Grant
-
2016
- 2016-03-27 IL IL244772A patent/IL244772B/en active IP Right Grant
- 2016-04-06 MX MX2021009222A patent/MX2021009222A/es unknown
- 2016-12-19 HK HK16114409A patent/HK1226671A1/zh unknown
-
2018
- 2018-11-05 JP JP2018208158A patent/JP6581279B2/ja active Active
- 2018-12-11 AU AU2018278880A patent/AU2018278880A1/en not_active Abandoned
-
2019
- 2019-03-24 IL IL265586A patent/IL265586A/en unknown
- 2019-03-28 ZA ZA2019/02009A patent/ZA201902009B/en unknown
- 2019-08-29 JP JP2019156399A patent/JP2019218386A/ja not_active Withdrawn
- 2019-11-28 HR HRP20192140TT patent/HRP20192140T1/hr unknown
- 2019-12-02 CY CY20191101260T patent/CY1122449T1/el unknown
-
2020
- 2020-11-03 AU AU2020264270A patent/AU2020264270B2/en active Active
-
2021
- 2021-01-15 US US17/150,379 patent/US20210155688A1/en active Pending
- 2021-07-30 JP JP2021125147A patent/JP7386208B2/ja active Active
-
2023
- 2023-11-13 JP JP2023192883A patent/JP2024016239A/ja active Pending
-
2024
- 2024-03-12 AU AU2024201615A patent/AU2024201615A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192140T1 (hr) | Režimi doziranja anti-folr1 imunokonjugata | |
US11834503B2 (en) | Anti-lag-3 antibodies and compositions | |
TWI780083B (zh) | 抗pd-1抗體及組成物 | |
AU2018355588C1 (en) | Anti-Galectin-9 antibodies and uses thereof | |
JP2019031568A5 (hr) | ||
RU2018111205A (ru) | Терапевтические комбинации, содержащие анти-folr1 иммуноконъюгаты | |
CN112584865A (zh) | 抗cd112r组合物和方法 | |
JP2016520082A5 (hr) | ||
JP2018527383A5 (hr) | ||
JP2017535257A5 (hr) | ||
RU2016124540A (ru) | Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака | |
RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
HRP20202047T1 (hr) | Antitijelo za igf-1r i njegova upotreba kao usmjeravajućeg vezikula za liječenje karcinoma | |
JP2017535246A5 (hr) | ||
CA3067416A1 (en) | Use of anti-fam19a5 antibodies for treating cancers | |
JP2020519675A5 (hr) | ||
RU2019141270A (ru) | Комбинации анти-folr1 иммуноконъюгатов и анти-pd-1 антител | |
KR20220057558A (ko) | 항-cd73 항체 | |
CN114599681B (zh) | 新型抗cd47抗体及其用途 | |
EP3625260A1 (en) | Treatment of cancer with anti-gitr agonist antibodies | |
JP2016525560A5 (hr) | ||
JP2024054123A (ja) | 癌の治療のための配合剤 | |
KR20160135764A (ko) | 이중-특이적 항원-결합 폴리펩티드 | |
CA3180188A1 (en) | Anti-flt3 antibodies and compositions | |
CN115485302A (zh) | 具有增强的激动剂活性的针对cd40的抗体 |